Analgesic Potential of Extracts and Derived Natural Products from Medicinal Plants

Since ancient times, plants have always been a reliable and important source of bioactive compounds used to treat several diseases, and thus play a central role in human health. In addition, medicinal plants are a rich source of bioactive secondary metabolites that have a wide range of medicinal uses. This is the reason why, currently, 90% of drugs come from natural or semisynthetic origins. Chemical diversity of plants made them one of the main sources for the extraction and purification of secondary metabolites. On the other hand, pain has always been a cause of concern to humans who searched for a remedy from natural sources, mostly from plants. In this respect, substances that relieve pain (algesia) can be described as analgesics (painkillers). Chemically diverse structures have been identified as pain relievers; they relieve pain through various mechanisms and act either centrally (opioids receptor agonism) or peripherally. Therefore, this chapter is intended to summarize the literature pertaining to plants and their constituents discovered with analgesic potential in the last four decades

Forecasting photovoltaic power generation with a stacking ensemble model

Nowadays, photovoltaics (PV) has gained popularity among other renewable energy sources because of its excellent features. However, the instability of the system’s output has become a critical problem due to the high PV penetration into the existing distribution system. Hence, it is essential to have an accurate PV power output forecast to integrate more PV systems into the grid and to facilitate energy management further. In this regard, this paper proposes a stacked ensemble algorithm (Stack-ETR) to forecast PV output power one day ahead, utilizing three machine learning (ML) algorithms, namely, random forest regressor (RFR), extreme gradient boosting (XGBoost), and adaptive boosting (AdaBoost), as base models. In addition, an extra trees regressor (ETR) was used as a meta learner to integrate the predictions from the base models to improve the accuracy of the PV power output forecast. The proposed model was validated on three practical PV systems utilizing four years of meteorological data to provide a comprehensive evaluation. The performance of the proposed model was compared with other ensemble models, where RMSE and MAE are considered the performance metrics. The proposed Stack-ETR model surpassed the other models and reduced the RMSE by 24.49%, 40.2%, and 27.95% and MAE by 28.88%, 47.2%, and 40.88% compared to the base model ETR for thin-film (TF), monocrystalline (MC), and polycrystalline (PC) PV systems, respectively

Systemic Review and Clinical Management in Diagnosis and Treatment of the Iron Deficiency Anemia in Adults

This study aimed at exploring with a systematic review the clinical management in diagnosis and treatment of the iron deficiency anemia in adults, as the iron deficiency is the most frequent cause of anemia worldwide. And it impairs quality of life, increases asthenia and can lead to clinical worsening of patients. In addition, iron deficiency has a complex mechanism whose pathologic pathway is recently becoming better understood. This review summarizes the current knowledge regarding diagnostic algorithms for iron deficiency anemia. The majority of aetiologies occur in the digestive tract, and justify morphological examination of the gut. First line investigations are upper gastrointestinal endoscopy and colonoscopy, and when negative, the small bowel should be explored; newer tools such as video capsule endoscopy have also been developed. The treatment of iron deficiency is aetiological if possible and iron supplementation whether in oral or in parenteral form

Fatty acids profiles and growth performances of Artemia franciscana fed with different types of microalgae

Artemia has been considered as one of the most important live diets for crustacean and finfish larviculture as well as broodstocks. However, the basal nutrient of Artemia has been reported to be poor in polyunsaturated fatty acids (PUFA’s) especially eicosapentaenoic acids (EPA) and docosahexaenoic acids (DHA), essential fatty acids for larval normal growth and gonad maturity in shrimp broodstocks. Thus, the present study aimed at investigating the effect of different microalgal diets on fatty acid content, growth performances and survival rate of Artemia francisciana. The study was performed by culturing instar I nauplii of A. franciscana for 12 days at a stocking density of 100 nauplii/L and fed with one of these microalgae: Chaetoceros calcitrans (T1), Dunaliella salina (T2), Tetraselmis chuii (T3), and Nanochloropsis oculata (T4). The results showed that the different microalgal diets affected fatty acid content, growth and survival rate of A. fransicana. The highest DHA content was obtained from those Artemia fed on D. salina, p<0.05. While DHA content of A. fransciscana fed with the other three microalgae was not significantly different, p>0.05. Another result indicated that EPA contents in the Artemia biomass were not significantly affected by the microalgal diets, p>0.05. In terms of growth and survival rate, A. franciscana fed on C. calcitrans and T. chuii had better growth and survival rate compared to that of Artemia fed on either D. salina or N. oculata, p<0.05. Due to the faster growth, it was also observed that Artemia fed on T. chuii started producing eggs on day 12. Further studies by feeding the Artemia with a mix of microalgal species either a mix of T. chuii and D. salina or a mix of C. calcitrans and D. salina are highly recommended for better PUFA contents, specific growth rate (SGR) as well as survival rates of Artemia

Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

Background: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD-linked variants; (2) provide harmonized and quality-controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD. Methods: We conducted a worldwide, systematic online survey to collect individual-level data on individuals with PD-linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ-1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed. Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ-1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published. Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD-linked variants; (2) provide harmonized and quality-controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene-targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Using global team science to identify genetic parkinson's disease worldwide.

No abstract available

Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)

Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic. Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality. Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121). Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic

Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

\ua9 2023, Springer Nature Limited. The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia

Embracing monogenic Parkinson's disease: the MJFF Global Genetic PD Cohort

© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Background: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD-linked variants; (2) provide harmonized and quality-controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD. Methods: We conducted a worldwide, systematic online survey to collect individual-level data on individuals with PD-linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ-1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype-phenotype relationships were analyzed. Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ-1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published. Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD-linked variants; (2) provide harmonized and quality-controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene-targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Michael J. Fox Foundation for Parkinson's Research. Grant Number: ID 15015.02. NIHR Cambridge Biomedical Research Centre. Grant Number: BRC-1215-20014info:eu-repo/semantics/publishedVersio